Department of Breast Pathology, King's College London, Guy's Hospital, London SE1 9RT, UK.
Department of Histopathology, University Hospitals Birmingham NHS Foundation Trust, Mindelsohn Way, Birmingham B15 2WB, UK.
Clin Radiol. 2018 Aug;73(8):682-692. doi: 10.1016/j.crad.2018.04.004.
Needle core biopsy is considered the histological diagnostic method of choice for screen-detected breast lesions. Although the majority are definitively diagnosed as normal, benign, or malignant, approximately 7% are categorised as B3, of uncertain malignant potential. These include a wide range of lesions with different risks of associated malignancy from <2% to approaching 40% from literature review in UK practice. Historically, these have typically been surgically excised as a diagnostic procedure but the majority are then proven to be benign. An alternative approach, for many of these lesions, is thorough sampling/excision by vacuum-assisted biopsy techniques to exclude the presence of co-existing carcinoma. This would potentially reduce the benign open biopsy rate whilst maintaining accuracy of cancer diagnosis. A group from the Radiology, Surgery, and Pathology NHS Breast Screening Programme Co-ordinating Committees and an additional co-opted expert were charged with review and development of guidelines for the clinical management of B3 lesions. The guidelines reflect suggested practice as stated by the NHS Breast Screening Programme and approved by the Royal College of Radiologists.
经皮空心针活检被认为是用于筛查发现的乳腺病变的组织学诊断方法。虽然大多数被明确诊断为正常、良性或恶性,但约 7%被归类为 B3,具有不确定的恶性潜能。这些病变包括广泛的不同恶性风险的病变,从文献回顾在英国实践中,其相关恶性风险从<2%到接近 40%不等。从历史上看,这些病变通常作为诊断程序进行手术切除,但大多数被证明是良性的。对于这些病变中的许多病变,一种替代方法是通过真空辅助活检技术进行彻底取样/切除,以排除共存癌的存在。这将有可能降低良性开放性活检率,同时保持癌症诊断的准确性。放射科、外科和病理学 NHS 乳房筛查计划协调委员会的一个小组和另外一个被选入的专家负责审查和制定 B3 病变的临床管理指南。这些指南反映了 NHS 乳房筛查计划规定的建议做法,并得到了皇家放射科医师学院的批准。